Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
September 2024 - Portal Instruments welcomes Matt Regan to its Board of Directors. Regan has held extensive leadership roles for prominent pharmaceutical companies such as Abbvie, Novo Nordisk and Micreos.
Matt Regan, a seasoned leader in the healthcare and life sciences industry, has recently joined the Board of Directors at Portal Instruments. This strategic move brings valuable expertise to Portal, a company focused on revolutionizing drug delivery through its innovative needle-free injection technology.
Regan's addition to the board underscores Portal Instruments' commitment to innovation and growth. His pharmaceutical insights and leadership will play a crucial role in shaping the company's future as it continues to advance its technology.
March 27th, 2020 Portal’s mission is to improve the experience for patients on life-changing therapies and that mission remains in the forefront of our minds as we, like everyone else, navigate these unchartered waters with the COVID-19 pandemic.
Today Portal Instruments announced the signing of a multi-million-dollar development agreement with a leading biotech company to advance its large-volume, reusable autoinjector, PRIME NEXUS™, toward clinical readiness in Q1 2027.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Please fill out the details below and we will get back to you shortly.